drugset / Trial / NCT04756765
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.
Timeline
- Start
- 2023-02-23
- Primary completion
- 2024-12-18
- Completion
- 2024-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | 1 mg | Oral |